| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Protein kinase C (PKC) is a potential molecular target, as DAG is an endogenous activator of conventional and novel PKC isoforms. However, 1,3-DAG is less effective than 1,2-DAG at activating PKC due to the 1,3 configuration which does not mimic the natural activator.
|
|---|---|
| ln Vitro |
In cell-free assays, 1,3-dimyristoyl-glycerol shows weak to no activation of PKC compared to 1,2-dimyristoyl-glycerol. It can serve as a substrate for diacylglycerol lipase (DAGL) and diacylglycerol kinase (DGK). Hydrolysis by pancreatic lipase yields 2-monoacylglycerol and free fatty acids.
|
| ln Vivo |
Dietary 1,3-diacylglycerols have been studied for their effects on postprandial lipemia and fat storage. In animal models, 1,3-dimyristoyl-glycerol reduces serum triglyceride levels and body fat accumulation compared to triacylglycerols, but the compound itself is not a drug.
|
| Enzyme Assay |
For PKC binding, a standard assay uses [3H]phorbol dibutyrate displacement in a PKC preparation. 1,3-DAG (0.1-100 uM) is incubated with PKC, Ca2+, phosphatidylserine, and the radioligand. However, 1,3-DAG typically shows much lower binding than 1,2-DAG.
|
| Cell Assay |
No specific cellular protocol. For studying DAG metabolism, cells (e.g., hepatocytes or adipocytes) are treated with 1,3-dimyristoyl-glycerol (10-200 uM) complexed with fatty acid-free BSA. After 1-24 hours, cellular DAG content, PKC translocation, or lipid droplet formation is analyzed.
|
| Animal Protocol |
In animal studies, 1,3-dimyristoyl-glycerol is often administered by oral gavage (e.g., 100-500 mg/kg) in a vehicle such as corn oil. Mice are then fasted, and blood is collected for triglyceride and fatty acid measurements. Tissue samples (liver, adipose) are taken for lipid analysis.
|
| ADME/Pharmacokinetics |
PK properties: 1,3-DAG is hydrolyzed in the intestine by pancreatic lipase to 2-monoacylglycerol and free myristic acid. The 2-monoacylglycerol is absorbed and re-esterified. It does not readily incorporate into chylomicrons as 1,2-DAG does. Formulation in oil for oral administration.
|
| Toxicity/Toxicokinetics |
General toxicity: Myristic acid is a saturated fatty acid with low toxicity. At high dietary levels, it may raise LDL cholesterol. The compound is generally recognized as safe (GRAS) as a food ingredient. Standard lab safety for lipids applies.
|
| Additional Infomation |
1,3-Dimyristoyl-glycerol is used as a reference standard for TLC and HPLC analysis of diacylglycerols in biological samples. It is also employed in studies of lipid metabolism, particularly investigating the differences between 1,2- and 1,3-diacylglycerols. This product is for research use only.
|
| Molecular Formula |
C31H60O5
|
|---|---|
| Molecular Weight |
512.81
|
| Exact Mass |
512.444
|
| CAS # |
7770-09-4
|
| Related CAS # |
1,3-Dimyristoyl-glycerol-d5;1246523-63-6
|
| PubChem CID |
82201
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.94g/cm3
|
| Boiling Point |
585.4ºC at 760 mmHg
|
| Flash Point |
170ºC
|
| Index of Refraction |
1.465
|
| LogP |
8.835
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
36
|
| Complexity |
438
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)O
|
| InChi Key |
JADYBWICRJWGBW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H60O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-30(33)35-27-29(32)28-36-31(34)26-24-22-20-18-16-14-12-10-8-6-4-2/h29,32H,3-28H2,1-2H3
|
| Chemical Name |
(2-hydroxy-3-tetradecanoyloxypropyl) tetradecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9500 mL | 9.7502 mL | 19.5004 mL | |
| 5 mM | 0.3900 mL | 1.9500 mL | 3.9001 mL | |
| 10 mM | 0.1950 mL | 0.9750 mL | 1.9500 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
